Cargando…

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials

OBJECTIVES: The aim of this integrated analysis is to evaluate the long-term safety and tolerability of ixekizumab in adults with psoriasis, PsA and axial SpA. METHODS: Integrated safety data from 21 clinical trials are presented by indication in patients who received at least one dose of ixekizumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Genovese, Mark C, Mysler, Eduardo, Tomita, Tetsuya, Papp, Kim A, Salvarani, Carlo, Schwartzman, Sergio, Gallo, Gaia, Patel, Himanshu, Lisse, Jeffrey R, Kronbergs, Andris, Leage, Soyi Liu, Adams, David H, Xu, Wen, Marzo-Ortega, Helena, Lebwohl, Mark G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733711/ https://www.ncbi.nlm.nih.gov/pubmed/32449924 http://dx.doi.org/10.1093/rheumatology/keaa189

Ejemplares similares

Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2021)

Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
por: Landewé, Robert B M, et al.
Publicado: (2023)

Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks
por: Deodhar, Atul, et al.
Publicado: (2021)

Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial
por: Deodhar, Atul, et al.
Publicado: (2020)

The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
por: Deodhar, Atul, et al.
Publicado: (2023)

The role of ixekizumab in non-radiographic axial spondyloarthritis
por: San Koo, Bon, et al.
Publicado: (2021)

Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
por: Landewé, Robert BM, et al.
Publicado: (2021)

Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
por: Braun, Jürgen, et al.
Publicado: (2022)

Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging
por: Maksymowych, Walter P, et al.
Publicado: (2022)

Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
por: Smolen, Josef S., et al.
Publicado: (2020)

Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis
por: Jadon, Deepak R, et al.
Publicado: (2017)

Axial spondyloarthritis and axial psoriatic arthritis: similar or different disease spectrum?
por: Benavent, Diego, et al.
Publicado: (2020)

Chondrocyte activity is increased in psoriatic arthritis and axial spondyloarthritis
por: Gudmann, Natasja Stæhr, et al.
Publicado: (2016)

Axial spondyloarthritis: coming of age
por: Marzo-Ortega, Helena
Publicado: (2020)

Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results
por: Deodhar, Atul A., et al.
Publicado: (2021)

Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial
por: Reich, Kristian, et al.
Publicado: (2022)

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
por: Coates, Laura C., et al.
Publicado: (2022)

Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis
por: Combe, Bernard, et al.
Publicado: (2020)

Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
por: Coates, Laura C., et al.
Publicado: (2022)

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
por: Mease, Philip J, et al.
Publicado: (2020)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
por: Braun, Juergen, et al.
Publicado: (2023)

Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry
por: Ciurea, Adrian, et al.
Publicado: (2023)

Characterization of Patients With Axial Spondyloarthritis by Enthesitis Presence: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2020)

Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52‐Week, Randomized, Controlled Trial
por: Walsh, Jessica A., et al.
Publicado: (2022)

Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H
por: Kristensen, Lars-Erik, et al.
Publicado: (2021)

Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis
por: Gladman, Dafna D., et al.
Publicado: (2019)

A Comparison of Disease Burden in Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis
por: Michelsen, Brigitte, et al.
Publicado: (2015)

Defining the target: clinical aims in axial spondyloarthritis
por: Marzo-Ortega, Helena, et al.
Publicado: (2018)

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
por: Dougados, Maxime, et al.
Publicado: (2020)

Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection
por: Miller, John, et al.
Publicado: (2021)

Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?
por: Harrison, S. R., et al.
Publicado: (2023)

Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52
por: Smolen, Josef S, et al.
Publicado: (2020)

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
por: Smolen, Josef S, et al.
Publicado: (2018)

Non-Physical Disease Facets in Spondyloarthritis: An ASAS Health Index-Based Analysis between Psoriatic Arthritis and Axial Spondyloarthritis
por: Queiro, Rubén, et al.
Publicado: (2022)

Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients
por: Garrido-Cumbrera, Marco, et al.
Publicado: (2017)

The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
por: McGonagle, Dennis G, et al.
Publicado: (2019)

Caesarean section in women with axial spondyloarthritis and psoriatic arthritis: a population-based study
por: Götestam Skorpen, Carina, et al.
Publicado: (2023)

Correction to: Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?
por: Harrison, S. R., et al.
Publicado: (2023)

Correction: Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Publicado: (2018)

Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials
por: Smith, Saxon D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7dhsf5pvth37k4mncn3iranmup